Antonio J Vallejo-Vaz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1415159/antonio-j-vallejo-vaz-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45 papers	1,267 citations	19 h-index	35 g-index
54 ext. papers	1,768 ext. citations	6.5 avg, IF	4.36 L-index

#	Paper	IF	Citations
45	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
44	Cerebrovascular Disease and Statins.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 778740	5.4	1
43	Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. *Atherosclerosis*, **2021**, 338, 39-45	3.1	0
42	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. *Atherosclerosis*, **2021**, 320, 1-9	3.1	1
41	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. *Atherosclerosis*, **2021**, 325, 46-56	3.1	5
40	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
39	Effect of computerised, knowledge-based, clinical decision support systems on patient-reported and clinical outcomes of patients with chronic disease managed in primary care settings: a systematic review.. *BMJ Open*, **2021**, 11, e054659	3	2
38	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. *Circulation*, **2020**, 141, 1742-1759	16.7	117
37	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. *European Journal of Preventive Cardiology*, **2020**, 27, 1663-1674	3.9	1
36	Triglycerides and residual risk. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2020**, 27, 95-103	4	20
35	Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?. *Current Opinion in Lipidology*, **2020**, 31, 111-118	4.4	8
34	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. *JAMA Cardiology*, **2020**, 5, 217-229	16.2	85
33	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. *Atherosclerosis*, **2019**, 288, 194-202	3.1	35
32	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. *Atherosclerosis*, **2019**, 288, 85-93	3.1	10
31	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65
30	Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year [illegible]	16.7	0
29	: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9. *European Cardiology Review*, **2018**, 13, 7-8	3.9	

28	Epidemiology of familial hypercholesterolaemia: Community and clinical. *Atherosclerosis*, **2018**, 277, 289-297	3.1	19
27	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
26	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. *Journal of the American Heart Association*, **2018**, 7, e009221	6	4
25	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). *American Journal of Cardiology*, **2017**, 119, 1352-1358	3	18
24	Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. *American Journal of Hypertension*, **2017**, 30, 673-682	2.3	21
23	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. *Circulation*, **2017**, 136, 1878-1891	16.7	92
22	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. *Thrombosis and Haemostasis*, **2016**, 116, 162-71	7	24
21	Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. *Pharmacological Research*, **2016**, 111, 163-179	10.2	17
20	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atherosclerosis Supplements*, **2016**, 22, 1-32	1.7	60
19	The evolving role of CETP inhibition: beyond HDL cholesterol. *Lancet, The*, **2015**, 386, 412-4	40	9
18	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. *Atherosclerosis*, **2015**, 241, 409-18	3.1	63
17	Familial hypercholesterolaemia: A global call to arms. *Atherosclerosis*, **2015**, 243, 257-9	3.1	123
16	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. *European Cardiology Review*, **2015**, 10, 37-41	3.9	3
15	Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?. *Circulation Research*, **2015**, 116, 1646-8	15.7	5
14	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. *Atherosclerosis*, **2015**, 241, 62-8	3.1	14
13	Obstructive sleep apnoea syndrome, endothelial function and markers of endothelialization. Changes after CPAP. *PLoS ONE*, **2015**, 10, e0122091	3.7	25
12	Maternal body-mass index and cord blood circulating endothelial colony-forming cells. *Journal of Pediatrics*, **2014**, 164, 566-571	3.6	10
11	Obstructive sleep apnea syndrome, vascular pathology, endothelial function and endothelial cells and circulating microparticles. *Archives of Medical Research*, **2013**, 44, 409-14	6.6	27

10	Coexistence of two causes of secondary hypertension in a single patient. *Revista Clinica Espanola*, **2013**, 213, e81-e83	0.7	
9	Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. *American Journal of Hypertension*, **2013**, 26, 1377-80	2.3	31
8	Isolated abducens nerve palsy in preeclampsia and hypertension in pregnancy. *Hypertension Research*, **2013**, 36, 834-5	4.7	13
7	Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy. *Hypertension Research*, **2012**, 35, 274-8	4.7	12
6	Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. *American Journal of Hypertension*, **2012**, 25, 1299-304	2.3	138
5	Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by laser-Doppler flowmetry?. *Coronary Artery Disease*, **2012**, 23, 57-61	1.4	24
4	The HELLP syndrome (hemolysis, elevated liver enzymes and low platelets): Clinical characteristics and maternal-fetal outcome in 172 patients. *Pregnancy Hypertension*, **2011**, 1, 164-9	2.6	11
3	Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. *International Journal of Hypertension*, **2011**, 2011, 685238	2.4	34
2	The Postprandial State and its Influence on the Development of Atherosclerosis. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2011**, 11, 1-9		1
1	Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. *Hypertension Research*, **2010**, 33, 1012-7	4.7	5